Patents Examined by Daniel R Carcanague
  • Patent number: 11884629
    Abstract: Provided are embodiments of para-substituted 1,1-dialkyl-4-phenylpiperazin-1-ium iodides advantageous for modulating inflammation that have been synthesized and their electrophysiology activities for ?9, ?9?10, and ?7 nAChRs compared. The para position contained alkyl or aryl amides, or heterocyclic isosteres for the amide, and the alkyl groups were varied at the ammonium piperazine nitrogen to see if compensatory changes in size at this position of the molecule impacted function. The compounds were characterized with two-electrode voltage-clamp measurements on Xenopus oocytes expressing nAChRs. General, the compounds were more potent for ?9-containing receptors than for ?7, and the majority were either full or strong partial agonists for ?9-containing nAChR.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: January 30, 2024
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Nicole Alana Horenstein, Roger Lee Papke, Hina Andleeb
  • Patent number: 11883381
    Abstract: Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, David Rogawski, Dmitry Borkin, Szymon Klossowski, Zhuang Jin, Deanna Montgomery, Jing Deng, Marta Krotoska, Hao Li
  • Patent number: 11884649
    Abstract: Disclosed herein, inter alia, are compounds for inhibiting IRE1? and uses thereof.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: January 30, 2024
    Assignees: The Regents of the University of California, University of Washington
    Inventors: Feroz R. Papa, Bradley J. Backes, Dustin J. Maly
  • Patent number: 11884638
    Abstract: The present disclosure relates to a novel compound or a salt thereof, a composition for detecting cysteine, a fluorescent probe, and a composition for diagnosing cancer, which contain the same, a method for detecting cysteine, a method for providing information for diagnosing cancer, and a method for producing the novel compound. According to the present disclosure, there may be provided a method of synthesizing and purifying a fluorescent probe for cysteine detection and applying the same to diagnose cervical cancer by detecting cysteine in human urine.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: January 30, 2024
    Inventors: Do Kyoung Kim, Chang Wook Jeong, Jong Min An
  • Patent number: 11883386
    Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: January 30, 2024
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D Greis, Angelique Sun Boyer, Namal C. Warshakoon
  • Patent number: 11885818
    Abstract: The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: January 30, 2024
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Hans-Peter Josel, Uwe Kobold, Christoph Seidel, Martin Rempt, Andreas Leinenbach, Giuseppe Prencipe, Silvia Baecher, Simon Ferdinand Loibl, Anna-Skrollan Geiermann, Jelena Milic, Nicole Pirkl
  • Patent number: 11878020
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • Patent number: 11872219
    Abstract: The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: January 16, 2024
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Barton Harley Manning
  • Patent number: 11866433
    Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: January 9, 2024
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Chunli Shen, Chengde Wu, Shenglin Chen, Shuhui Chen, Xiquan Zhang, Xin Tian
  • Patent number: 11858945
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: January 2, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or
  • Patent number: 11858946
    Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: January 2, 2024
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Michelle Richter, Andrew Riley, Bryon S. Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia
  • Patent number: 11851442
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: December 26, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • Patent number: 11845744
    Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: December 19, 2023
    Assignee: Skyhawk Therapeutics, Inc.
    Inventors: Michael Luzzio, Brian Lucas, Daniel Brian Horne, Tiansheng Wang
  • Patent number: 11845741
    Abstract: The present disclosure provides pilocarpine ionic liquid analogs useful in the treatment of ophthalmological disorders such as glaucoma.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: December 19, 2023
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION
    Inventors: Juan Wang, Hu Yang
  • Patent number: 11845728
    Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: December 19, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Michael Erb, Jun Qi
  • Patent number: 11840549
    Abstract: Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 12, 2023
    Assignees: BIOVINC, LLC, UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Frank H. Ebetino, Shuting Sun, Mark W. Lundy, Charles E. McKenna, Eric Richard, Parish Sedghizadeh, Keivan Sadrerafi, Philip T. Cherian
  • Patent number: 11827645
    Abstract: Disclosed is a compound of Formula I or a pharmaceutically acceptable salt thereof, preparation methods thereof, pharmaceutical composition comprising the same, and use thereof in the treatment of diseases such as pancreatic cancer.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: November 28, 2023
    Assignee: CHONGQING UNIVERSITY OF ARTS AND SCIENCES
    Inventors: Zhigang Xu, Zhongzhu Chen, Dianyong Tang
  • Patent number: 11827641
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: November 28, 2023
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
  • Patent number: 11827638
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • Patent number: 11826341
    Abstract: A method of treating an ocular nerve injury in a subject in need thereof, the method comprising administering a therapeutically effective amount of baicalein or an analog thereof.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: November 28, 2023
    Assignees: THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Chi Wai Do, Chi ho To, Li Pan, Dongfeng Chen, Kin-Sang Cho